NCT07298421

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-08-18Est. Completion: 2030-05-31

Enrollment target: 100 participants

Locations

NYU Langone Health, New York, New York, United States
Royal Children's Hospital, Parkville, Victoria, Australia
Perth Children's Hospital, Nedlands, Western Australia, Australia
CECIP - Centro de Estudos Clínicos do Interior Paulista, Jaú, São Paulo, Brazil
BR Trials - Pesquisa Clínica, São Paulo, São Paulo, Brazil
Centro de Investigación Clínica Acelerada, S.C, Mexico City, Mexico CITY (federal District), Mexico
FAICIC Clinical Research, Veracruz, Mexico
Emmed Research, Pretoria, Gauteng, South Africa
IATROS International, Bloemfontein, South Africa
National Taiwan University Hospital, Taipei, Taiwan
Chulalongkorn University, Bangkok, Thailand
Siriraj Hospital, Bangkok, Thailand
Ramathibodi Hospital, Bangkok, Thailand
Sheffield Childrens Hospital, Sheffield, United Kingdom

Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease

This study is a real - world clinical research of adalimumab. The project plans to enroll 30 subjects, aiming to evaluat…

Guangzhou, ChinaEst. completion Mar 2029

Inflammatory Bowel DiseasesCrohn's DiseaseSkin DiseasesDermatitis

The main objective of this study is to evaluate the change in the relative abundance of S. aureus within the lesion-site…

Millau, FranceEst. completion Sep 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.